{
  "ticker": "IONS",
  "company_name": "Ionis Pharmaceuticals",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT02414594",
      "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Elevated Lipoprotein(a)",
      "start_date": "2015-04",
      "completion_date": "2016-02",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT01710852",
      "title": "Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Paroxysmal Atrial Fibrillation",
      "start_date": "2012-10",
      "completion_date": "2014-04",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT00330200",
      "title": "Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Type 2 Diabetes Mellitus",
      "start_date": "2005-11-01",
      "completion_date": "2007-03-01",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04768972",
      "title": "FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Amyotrophic Lateral Sclerosis",
      "start_date": "2021-06-14",
      "completion_date": "2028-03",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT05314439",
      "title": "A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled Hypertension",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Hypertension",
      "start_date": "2022-04-29",
      "completion_date": "2023-02-15",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT00280995",
      "title": "Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Hypercholesterolemia, Familial",
      "start_date": "2006-01",
      "completion_date": "2007-08",
      "enrollment": 0,
      "sponsor": "Kastle Therapeutics, LLC"
    },
    {
      "nct_id": "NCT02900027",
      "title": "Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Elevated Triglycerides (TG)",
      "start_date": "2016-09",
      "completion_date": "2018-04-30",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT00048113",
      "title": "Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Crohn's Disease",
      "start_date": "2001-01-10",
      "completion_date": "2002-04-27",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT00063414",
      "title": "ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Ulcerative Colitis",
      "start_date": "2002-11-20",
      "completion_date": "2005-03-24",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT03263507",
      "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen (IONIS-PKK-LRx) Administered Subcutaneously to Healthy Volunteers",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteers",
      "start_date": "2017-08-28",
      "completion_date": "2018-10-09",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE1": 11,
      "PHASE2": 23,
      "PHASE3": 9,
      "PHASE1, PHASE2": 3,
      "": 3,
      "PHASE2, PHASE3": 1
    },
    "by_status": {
      "COMPLETED": 35,
      "TERMINATED": 4,
      "ACTIVE_NOT_RECRUITING": 9,
      "WITHDRAWN": 2
    },
    "active_trials": 9,
    "completed_trials": 35,
    "conditions": [
      "Abnormalities, Cardiovascular",
      "Acromegaly",
      "Amyloidosis",
      "Amyotrophic Lateral Sclerosis",
      "Beta Thalassemia Intermedia",
      "Crohn's Disease",
      "Elevated Lipoprotein(a)",
      "Elevated Lipoprotein(a), Cardiovascular Disease",
      "Elevated Triglycerides (TG)",
      "End-stage Renal Disease (ESRD)",
      "Familial Chylomicronemia Syndrome",
      "Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia Type 1",
      "Familial Partial Lipodystrophy",
      "Geographic Atrophy, Age Related Macular Degeneration",
      "Healthy",
      "Healthy Participants",
      "Healthy Volunteers",
      "Healthy Volunteers, hATTR Amyloidosis",
      "Hepatitis C, Chronic",
      "Hereditary Amyloidosis, Transthyretin-Related",
      "Hereditary Angioedema",
      "Hereditary Transthyretin-Mediated Amyloid Polyneuropathy",
      "Hypercholesterolemia",
      "Hypercholesterolemia, Familial",
      "Hypertension",
      "Hypertriglyceridemia",
      "Hypertriglyceridemia, Cardiovascular Diseases",
      "Macular Degeneration, Geographic Atrophy",
      "Parkinson's Disease",
      "Paroxysmal Atrial Fibrillation",
      "Primary IgA Nephropathy",
      "Prion Disease",
      "Severe Hypertriglyceridemia",
      "Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)",
      "Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)",
      "Type 2 Diabetes",
      "Type 2 Diabetes Mellitus",
      "Type 2 Diabetes Mellitus, Obese",
      "Ulcerative Colitis",
      "Venous Thromboembolism"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:02:51.216313",
    "search_query": "Ionis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/search?term=Ionis+Pharmaceuticals"
  }
}